Orgenesis Engages Liolios Group to Lead New Investor Relations Program

WHITE PLAINS, NY and TEL AVIV, ISRAEL--(Marketwired - Oct 3, 2013) - Orgenesis, Inc. (OTCQB: ORGS), a development-stage company with a novel regenerative medicine technology that converts a diabetes patient's liver cells into functioning insulin-producing cells, has engaged Liolios Group to lead a new investor relations and financial communications program.

"We have reached an important stage in our development where all the key elements we need to begin our Phase 1B clinical trials are rapidly coming together," says Sav DiPasquale, Chief Executive Officer of Orgenesis. "This ranges from successful pre-clinical studies and key industry partnerships to the strengthening of our board and scientific advisory board with leaders in the field, as well as progress on our manufacturing process development and encouraging discussions with U.S. and European regulatory agencies."

"Given our momentum, we believe the time has come to engage a team of investor relations professionals to help us better communicate our story to our shareholders and the financial community at large," continued DiPasquale. "Liolios Group has a proven track record of helping companies like Orgenesis enhance its shareholder value."

Liolios Group will work closely with Orgenesis' management to refine and deliver the company's message, and make introductions to key investors and influencers in the financial community. They will also assist the company in scheduling road shows and financial conferences over the next several months.

To arrange for a call or meeting with management, contact Justin Vaicek at (949) 574-3860 or justin@liolios.com.

About Liolios Group Inc.
Liolios Group is an investor relations firm specializing in micro to mid-cap companies. The firm aims to deliver superior performance in corporate messaging and positioning, investor awareness, analyst and financial press coverage and capital attraction. Founded in 1999, Liolios Group executives have extensive experience in financial and investments and represent clients in a wide range of industries, including life sciences/healthcare, consumer/internet retail, business services, digital, media/software, clean technology, technology, natural resources and special situations. For more information about Liolios Group, visit www.liolios.com.

About Orgenesis Inc.
Orgenesis (ORGS) is a development stage company with a novel therapeutic technology that employs a molecular and cellular approach directed at converting a patient's own liver cells into functional insulin producing cells, as a treatment for diabetes. The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. For more information visit: www.orgenesis.com.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes which could, if successful, mean the end of diabetes as we know it; that we have an advantage over competitors with our approach to treating diabetes; and that our Phase 1B clinical trials are rapidly coming together. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase;, our ability to retain key employees; our ability to finance development or satisfy the rigorous regulatory requirements for new medical procedures; and competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.